Healthcare stocks were declining premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.6% and the iShares Biotechnology ETF (IBB) 0.1% lower.
Humana (HUM) shares were up more than 4% after the company said it plans to reaffirm its full-year adjusted earnings guidance of at least $9 per share during upcoming meetings.
GRAIL's (GRAL) stock was down more than 17% after the company said the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint.
Biohaven (BHVN) shares were up more than 1% after the company said it has initiated first-in-human dosing of BHV-8100, an experimental oral, brain-penetrant PKM2 modulator being developed for neurological, retinal and inflammatory diseases.